{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T16:04:02Z","timestamp":1791043442638,"version":"4.1.0"},"reference-count":28,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2004,11,15]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> To evaluate the safety and efficacy of CT-2103, a novel conjugate of paclitaxel and poly-l-glutamic acid, in heavily pretreated patients with recurrent ovarian, fallopian tube, or peritoneal cancer. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> Ninety-nine patients with measurable disease received intravenous CT-2103 at 175 mg\/m<jats:sup>2<\/jats:sup> of conjugated paclitaxel over 10 minutes every 3 weeks without routine premedications. Platinum-sensitive (n = 42) and platinum-refractory or platinum-resistant patients (n = 57) were enrolled. Thirty-nine patients (39%) had received one or two prior regimens, and 60 patients (61%) had received between three and 12 regimens. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> In 99 patients, the median number of cycles was three (range, one to 14 cycles). The response rate (RR) for all patients was 10% (10 of 99 patients), with median time to disease progression (TTP) of 2 months. The RR (partial response) in platinum-sensitive and platinum-resistant patients was 14% (six of 42 patients) and 7% (four of 57 patients), respectively. In patients with only one or two prior regimens, the RR in platinum-sensitive and platinum-resistant patients was 28% (five of 18 patients) and 10% (two of 21 patients), with a median TTP of 4 and 2 months, respectively. Grade 2 (15 patients) or 3 (15 patients) neuropathy was reported in 30 patients (30%). Grade 2 hypersensitivity occurred in eight patients (8%) who were subsequently treated with premedications; one patient had grade 3 hypersensitivity and was removed. Grade 2 alopecia was absent. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> CT-2103 is active in patients with recurrent ovarian cancer. Neurotoxicity in these heavily pretreated patients was more frequent than predicted from phase I trials. Further study to define toxicity and efficacy in patients with less prior therapy is ongoing. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2004.12.043","type":"journal-article","created":{"date-parts":[[2004,11,12]],"date-time":"2004-11-12T23:27:57Z","timestamp":1100302077000},"page":"4523-4531","source":"Crossref","is-referenced-by-count":108,"title":["Phase II Study of CT-2103 in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma"],"prefix":"10.1200","volume":"22","author":[{"given":"Paul","family":"Sabbatini","sequence":"first","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer Center, New York, NY; Gynecology Oncology Associates, Newport Beach, CA; Pacific Gynecology Specialists; Virginia Mason Medical Center; Swedish Medical Center and Cancer Institute; Cell Therapeutics, Inc, Seattle, WA; and Southwest Regional Cancer Center, Austin, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Aghajanian","sequence":"additional","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer Center, New York, NY; Gynecology Oncology Associates, Newport Beach, CA; Pacific Gynecology Specialists; Virginia Mason Medical Center; Swedish Medical Center and Cancer Institute; Cell Therapeutics, Inc, Seattle, WA; and Southwest Regional Cancer Center, Austin, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don","family":"Dizon","sequence":"additional","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer Center, New York, NY; Gynecology Oncology Associates, Newport Beach, CA; Pacific Gynecology Specialists; Virginia Mason Medical Center; Swedish Medical Center and Cancer Institute; Cell Therapeutics, Inc, Seattle, WA; and Southwest Regional Cancer Center, Austin, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sybil","family":"Anderson","sequence":"additional","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer Center, New York, NY; Gynecology Oncology Associates, Newport Beach, CA; Pacific Gynecology Specialists; Virginia Mason Medical Center; Swedish Medical Center and Cancer Institute; Cell Therapeutics, Inc, Seattle, WA; and Southwest Regional Cancer Center, Austin, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Dupont","sequence":"additional","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer Center, New York, NY; Gynecology Oncology Associates, Newport Beach, CA; Pacific Gynecology Specialists; Virginia Mason Medical Center; Swedish Medical Center and Cancer Institute; Cell Therapeutics, Inc, Seattle, WA; and Southwest Regional Cancer Center, Austin, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John V.","family":"Brown","sequence":"additional","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer Center, New York, NY; Gynecology Oncology Associates, Newport Beach, CA; Pacific Gynecology Specialists; Virginia Mason Medical Center; Swedish Medical Center and Cancer Institute; Cell Therapeutics, Inc, Seattle, WA; and Southwest Regional Cancer Center, Austin, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Peters","sequence":"additional","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer Center, New York, NY; Gynecology Oncology Associates, Newport Beach, CA; Pacific Gynecology Specialists; Virginia Mason Medical Center; Swedish Medical Center and Cancer Institute; Cell Therapeutics, Inc, Seattle, WA; and Southwest Regional Cancer Center, Austin, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Jacobs","sequence":"additional","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer Center, New York, NY; Gynecology Oncology Associates, Newport Beach, CA; Pacific Gynecology Specialists; Virginia Mason Medical Center; Swedish Medical Center and Cancer Institute; Cell Therapeutics, Inc, Seattle, WA; and Southwest Regional Cancer Center, Austin, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aminder","family":"Mehdi","sequence":"additional","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer Center, New York, NY; Gynecology Oncology Associates, Newport Beach, CA; Pacific Gynecology Specialists; Virginia Mason Medical Center; Swedish Medical Center and Cancer Institute; Cell Therapeutics, Inc, Seattle, WA; and Southwest Regional Cancer Center, Austin, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saul","family":"Rivkin","sequence":"additional","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer Center, New York, NY; Gynecology Oncology Associates, Newport Beach, CA; Pacific Gynecology Specialists; Virginia Mason Medical Center; Swedish Medical Center and Cancer Institute; Cell Therapeutics, Inc, Seattle, WA; and Southwest Regional Cancer Center, Austin, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy J.","family":"Eisenfeld","sequence":"additional","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer Center, New York, NY; Gynecology Oncology Associates, Newport Beach, CA; Pacific Gynecology Specialists; Virginia Mason Medical Center; Swedish Medical Center and Cancer Institute; Cell Therapeutics, Inc, Seattle, WA; and Southwest Regional Cancer Center, Austin, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Spriggs","sequence":"additional","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer Center, New York, NY; Gynecology Oncology Associates, Newport Beach, CA; Pacific Gynecology Specialists; Virginia Mason Medical Center; Swedish Medical Center and Cancer Institute; Cell Therapeutics, Inc, Seattle, WA; and Southwest Regional Cancer Center, Austin, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199601043340101"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.14.3312"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.5.1062"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.6.2183"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(02)00045-5"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-3659(98)00009-1"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19980209)75:4<600::AID-IJC18>3.0.CO;2-C"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1007\/s002800000168"},{"key":"R9","unstructured":"Li C, Yu DF, Newman RA, et al: Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate. Cancer Res 58:2404,1998\u20132409,"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2001.6331"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.9.1748"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2000.5958"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.12.2405"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.3.796"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008240421028"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.7.1893"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.3.389"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/86.20.1530"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.9.2546"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.02.091"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1080\/028418602320404998"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.082"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1179\/joc.1999.11.4.301"},{"key":"R26","doi-asserted-by":"crossref","unstructured":"Armstrong D, O'Reilly S: Clinical guidelines for managing topotecan-related hematologic toxicity. Oncologist 3:4,1998\u201310,","DOI":"10.1634\/theoncologist.3-1-4"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199504133321507"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.7.1263"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2004.12.043","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:58:28Z","timestamp":1653512308000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2004.12.043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11,15]]},"references-count":28,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2004,11,15]]}},"alternative-id":["10.1200\/JCO.2004.12.043"],"URL":"https:\/\/doi.org\/10.1200\/jco.2004.12.043","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,11,15]]}}}